Drug intelligence / Profile preview

aldesleukin + lymphokine-activated killer cells

Development stage: Unknown
Lead developer: Novartis
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies
Administration: Intracavitary

Overview

Aldesleukin + lymphokine-activated killer (LAK) cells is an investigational combination immunotherapy regimen evaluated by Weill Medical College of Cornell University for the treatment of malignant gliomas. Aldesleukin is a recombinant form of interleukin-2 (IL-2) that acts as a potent T-cell growth factor and activator of natural killer (NK) cells by binding to IL-2 receptors. In this specific therapeutic approach, aldesleukin is administered intracavitary (directly into the tumor cavity) alongside autologous LAK cells—patient-derived lymphocytes that have been activated and expanded ex vivo with IL-2. This localized delivery is intended to bypass the blood-brain barrier and stimulate a targeted immune response against primary, recurrent, or refractory brain tumors by enhancing the cytolytic activity of the infused immune cells within the tumor microenvironment.

Brand names: Proleukin
Other names: IL-2IL2IL 2interleukin-2interleukin2interleukin 2LAK cellsautologous lymphokine-activated killer cellsrecombinant human interleukin-2

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on aldesleukin + lymphokine-activated killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aldesleukin + lymphokine-activated killer cells.

Explore the full profile